Literature DB >> 19351955

Factor XI contributes to thrombin generation in the absence of factor XII.

Dmitri V Kravtsov1, Anton Matafonov, Erik I Tucker, Mao-Fu Sun, Peter N Walsh, Andras Gruber, David Gailani.   

Abstract

During surface-initiated blood coagulation in vitro, activated factor XII (fXIIa) converts factor XI (fXI) to fXIa. Whereas fXI deficiency is associated with a hemorrhagic disorder, factor XII deficiency is not, suggesting that fXI can be activated by other mechanisms in vivo. Thrombin activates fXI, and several studies suggest that fXI promotes coagulation independent of fXII. However, a recent study failed to find evidence for fXII-independent activation of fXI in plasma. Using plasma in which fXII is either inhibited or absent, we show that fXI contributes to plasma thrombin generation when coagulation is initiated with low concentrations of tissue factor, factor Xa, or alpha-thrombin. The results could not be accounted for by fXIa contamination of the plasma systems. Replacing fXI with recombinant fXI that activates factor IX poorly, or fXI that is activated poorly by thrombin, reduced thrombin generation. An antibody that blocks fXIa activation of factor IX reduced thrombin generation; however, an antibody that specifically interferes with fXI activation by fXIIa did not. The results support a model in which fXI is activated by thrombin or another protease generated early in coagulation, with the resulting fXIa contributing to sustained thrombin generation through activation of factor IX.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351955      PMCID: PMC2714215          DOI: 10.1182/blood-2009-02-203604

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX.

Authors:  M F Sun; M Zhao; D Gailani
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

2.  The thrombogram: monitoring thrombin generation in platelet-rich plasma.

Authors:  H C Hemker; P L Giesen; M Ramjee; R Wagenvoord; S Béguin
Journal:  Thromb Haemost       Date:  2000-04       Impact factor: 5.249

3.  Blood coagulation factors in the black headed vulture (Coragyps atratus), a potential animal model for the study of haemostasis.

Authors:  Jesus Weir-M; Zulay Acurero; Rodolfo Salas-A; M Arteaga-Vizcaino
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

4.  The role of factor XI in thrombin generation induced by low concentrations of tissue factor.

Authors:  I M Keularts; A Zivelin; U Seligsohn; H C Hemker; S Béguin
Journal:  Thromb Haemost       Date:  2001-06       Impact factor: 5.249

5.  Comparative blood coagulation studies in the ostrich.

Authors:  C L Frost; R J Naudé; W Oelofsen; B Jacobson
Journal:  Immunopharmacology       Date:  1999-12

6.  Hageman factor (factor XII) deficiency in marine mammals.

Authors:  A J Robinson; M Kropatkin; P M Aggeler
Journal:  Science       Date:  1969-12-12       Impact factor: 47.728

7.  Congenital factor XI deficiency in a domestic shorthair cat.

Authors:  Mark T Troxel; Marjory B Brooks; Meredith L Esterline
Journal:  J Am Anim Hosp Assoc       Date:  2002 Nov-Dec       Impact factor: 1.023

8.  Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available.

Authors:  Simone J H Wielders; Suzette Béguin; H Coenraad Hemker; Theo Lindhout
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-04-08       Impact factor: 8.311

9.  Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI.

Authors:  Frank A Baglia; David Gailani; José A López; Peter N Walsh
Journal:  J Biol Chem       Date:  2004-08-17       Impact factor: 5.157

10.  The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa.

Authors:  Aysar Aktimur; Melanie A Gabriel; David Gailani; John R Toomey
Journal:  J Biol Chem       Date:  2002-12-20       Impact factor: 5.157

View more
  58 in total

1.  Evidence against a protein in plasma that is a product of a factor XI mRNA splice variant missing exons 6 and 7.

Authors:  David Gailani; Mao-Fu Sun; Qiufang Cheng; Anton Matafonov; Erik I Tucker; Andras Gruber; Jonas Emsley
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

2.  Biorheology of platelet activation in the bloodstream distal to thrombus formation.

Authors:  Jevgenia Zilberman-Rudenko; Asako Itakura; Jeevan Maddala; Sandra M Baker-Groberg; Ralf Vetter; Erik I Tucker; András Gruber; Christoph Gerdes; Owen J T McCarty
Journal:  Cell Mol Bioeng       Date:  2016-05-26       Impact factor: 2.321

3.  Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.

Authors:  Rami A Al-Horani; David Gailani; Umesh R Desai
Journal:  Thromb Res       Date:  2015-04-22       Impact factor: 3.944

4.  The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.

Authors:  Katrin F Nickel; Göran Ronquist; Florian Langer; Linda Labberton; Tobias A Fuchs; Carsten Bokemeyer; Guido Sauter; Markus Graefen; Nigel Mackman; Evi X Stavrou; Gunnar Ronquist; Thomas Renné
Journal:  Blood       Date:  2015-07-07       Impact factor: 22.113

5.  Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates.

Authors:  C Puy; E I Tucker; Z C Wong; D Gailani; S A Smith; S H Choi; J H Morrissey; A Gruber; O J T McCarty
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

Review 6.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 7.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

8.  Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo.

Authors:  Jevgenia Zilberman-Rudenko; Stéphanie E Reitsma; Cristina Puy; Rachel A Rigg; Stephanie A Smith; Erik I Tucker; Robert Silasi; Alona Merkulova; Keith R McCrae; Coen Maas; Rolf T Urbanus; David Gailani; James H Morrissey; András Gruber; Florea Lupu; Alvin H Schmaier; Owen J T McCarty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

9.  Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.

Authors:  Christina U Lorentz; Norah G Verbout; Michael Wallisch; Matthew W Hagen; Joseph J Shatzel; Sven R Olson; Cristina Puy; Monica T Hinds; Owen J T McCarty; David Gailani; András Gruber; Erik I Tucker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

10.  A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.

Authors:  Yasin Kokoye; Ivan Ivanov; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Shauna Mason; Daniel J Sexton; Thomas Renné; Keith McCrae; Edward P Feener; David Gailani
Journal:  Thromb Res       Date:  2016-02-18       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.